“ Improved VELOS„ manufacturing process delivering higher cNeT doses “ “ Protocols updated to evaluate the benefit of enhanced host conditioning, with further data expected in 2H 2024 “ “ First...
“ Provided interim Phase I/IIa update on clonal neoantigen reactive T cells in advanced NSCLC and melanoma “ “ Improved VELOS„ manufacturing process delivering higher cNeT doses “ “ Protocols...
LONDON, Feb. 05, 2024 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
LONDON, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
“ On track to dose 15-20 patients with higher dose cNeT by year-end 2023 “ “ Clinical and translational science data update from the ongoing Phase I/IIa trials in NSCLC and melanoma expected in Q1...
LONDON, Sept. 22, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
- Clinical and translational science data expected in the fourth quarter of 2023 from the ongoing Phase I/IIa trials in NSCLC and melanoma - - neoRanker„¢ immunogenicity prediction module of PELEUS„¢...
LONDON, May 10, 2023 (GLOBE NEWSWIRE) -- Achilles Therapeutics plc (NASDAQ: ACHL), a clinical-stage biopharmaceutical company developing AI-powered precision T cell therapies targeting clonal...
- Phase I/IIa clinical trials in NSCLC and melanoma progressing with additional clinical and translational science data expected in the fourth quarter of 2023 - - Strong cash position of $158.5...
Achilles Therapeutics Announces Grant of US Patent Covering the Treatment of Patients with an Immunotherapy Targeting Neoantigens Based on Tumor HLA Status